Nifty Pharma News and Updates

Name: Latest research reports of Mankind Pharma Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Mankind Pharma Ltd.
Rating: 4
Author: Geojit BNP Paribas

Keep track of all breaking news on Nifty Pharma from all sources in a single place.

Cipla Ltd.

16 Jun 2026, 10:36PM

1373.20

-0.59%

Cipla appoints Shivam Puri as CEO of 'One India Business' from July 1

Business Standard

Homegrown pharma major Cipla Ltd on Tuesday announced the appointment of Shivam Puri as the CEO of its 'One India Business' with effect from July 1, 2026. Puri, currently Managing Director and CEO of Cipla Health Ltd, a wholly-owned subsidiary of the company, has over 23 years of leadership experience across both FMCG and healthcare sectors. He brings strong commercial acumen and consumer-centric expertise, Cipla said in a regulatory filing. He took over as MD and CEO of Cipla Health in 2019, and under his leadership, the company rapidly expanded its portfolio and strengthened its presence across key consumer categories, such as smoking cessation, pain care, cough and cold, skin care, hair care and nutrition, among others, Cipla said. Before joining Cipla Health in 2019, Puri held senior leadership roles at Hindustan Unilever, Jubilant FoodWorks and ITC Ltd, the filing said.

Cipla Ltd. is trading above its 100 day SMA of 1323.8

Cipla Ltd.

16 Jun 2026, 04:52PM

1373.20

-0.59%

Cipla expands respiratory, specialty manufacturing across India, China, US

Business Standard

The drugmaker has approved investments of over Rs 4,000 crore in the past two years to expand respiratory APIs, oncology ingredients, inhalation products and global manufacturing capacity

Cipla Ltd. has an average target of 1553.22 from 9 brokers.

Biocon Ltd.

16 Jun 2026, 02:05PM

416.45

0.10%

Biocon aims to become world's top insulin supplier in five years

Business Line

Chairperson Kiran Mazumdar-Shaw sees opportunity as global pharma giants pivot to GLP-1 therapies.

Biocon Ltd. has an average target of 398.80 from 5 brokers.

Mankind Pharma Ltd.

16 Jun 2026, 12:00AM

2356.20

-1.01%

MANKIND PHARMA LIMITED

Accumulate: Mankind Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Mankind Pharma is a multinational pharmaceutical and healthcare product company, headquartered in Delhi. It manufactures products in therapeutic areas ranging from...

Mankind Pharma Ltd. is trading below its 30 day SMA of 2408.1

Piramal Pharma Ltd.

14 Jun 2026

163.67

-2.11%

Piramal Pharma to stay away from generic GLP-1 race amid global rush

Business Standard

Piramal Pharma is avoiding the crowded GLP-1 peptide market, focusing instead on niche therapies and specialised manufacturing to drive CDMO growth in FY27

Piramal Pharma Ltd. has an average target of 225.00 from 3 brokers.

Torrent Pharmaceuticals Ltd.

14 Jun 2026

4466.70

-0.83%

Strong domestic market growth, margins to drive gains for Torrent Pharma

Business Standard

Torrent Pharma is benefiting from robust growth in the domestic market and healthy performance across key geographies, while synergies from JB Chemicals acquisition are expected to support earnings

Torrent Pharma has gained 37.33% in the last 1 Year

Dr. Reddy's Laboratories Ltd.

13 Jun 2026

1276.90

-0.20%

Dr Reddy's launches generic oral leukaemia drug Bosutinib in US market

Business Standard

The company has launched a generic version of Pfizer's Bosulif for chronic myeloid leukaemia and secured 180 days of exclusivity for the 400 mg strength

Dr. Reddy's Laboratories Ltd. is trading below its 30 day SMA of 1294.4

Dr Reddy's launches Bosutinib tablets in US market

Business Line | 13 Jun 2026

Wockhardt Ltd.

12 Jun 2026

1919.20

0.61%

Turnaround? Or execution still under scrutiny

Not Rated: Wockhardt Ltd.

Deven Choksey

Wockhardt has transformed into an innovation-led pharmaceutical company with a strong pipeline of novel antibiotics, highlighted by the USFDA approval of Zaynich.

Wockhardt has gained 58.44% in the last 3 Months

Cipla Ltd.

11 Jun 2026

1373.20

-0.59%

Cipla's Goa facility gets VAI classification from US FDA after inspection

Business Line

Under the VAI category, the US FDA does not recommend regulatory or enforcement action as the observations do not currently meet the threshold for further action.

Number of FII/FPI investors decreased from 1052 to 964 in Mar 2026 qtr

Biocon Ltd.

11 Jun 2026

416.45

0.10%

Biocon founder Kiran Mazumdar-Shaw says India needs patient capital for Biotech

Business Line

Biocon founder says India has the talent and scientific capability to build global biotech champions, but lacks the funding ecosystem needed to scale them.

Biocon Ltd. has an average target of 398.80 from 5 brokers.

Is Nifty Pharma worth buying?

342 Votes:

Buy 78.95%

Sell 11.99%

Hold 9.06%

Nifty Pharma PB	5.1
Nifty Pharma PE	36.9
Nifty Pharma DIV	0.8
Nifty Pharma EPS	654.3

Near 52W High of ₹25043.15

Nifty Pharma PB

Nifty Pharma PE

Nifty Pharma DIV

Nifty Pharma EPS

Nifty Pharma News and Updates

Keep track of all breaking news on Nifty Pharma from all sources in a single place.